Cyclacel Pharmaceuticals, Inc. is a biopharmaceutical firm currently in the clinical development stage, focused on discovering and advancing treatments for various cancers and other diseases involving abnormal cell growth. The company's active drug pipeline includes several promising candidates: Fadraciclib, a cyclin-dependent kinase (CDK) inhibitor, is presently undergoing Phase 1/2 clinical studies for solid tumors and is also being evaluated in combination with venetoclax for patients with chronic lymphocytic leukemia that has recurred or is resistant to previous therapies. CYC140, a polo-like kinase inhibitor, has progressed to Phase 1/2 clinical trials for the treatment of both advanced leukemias and solid malignancies. Sapacitabine, an innovative orally available nucleoside analog (a prodrug of CNDAC), is also in Phase 1/2 clinical trials, targeting acute myeloid leukemia and myelodysplastic syndrome. The pipeline further features Seliciclib, another CDK inhibitor, which is being investigated in investigator-sponsored trials (ISTs), including a Phase 2 study for Cushing's disease and a Phase 1/2 study for advanced rheumatoid arthritis. In a key strategic alliance, Cyclacel has collaborated with the University of Texas MD Anderson Cancer Center. This partnership aims to clinically assess the safety and therapeutic potential of three of Cyclacel's compounds in patients with a range of blood cancers, such as chronic lymphocytic leukemias, acute myeloid leukemias, myelodysplastic syndromes, and other forms of advanced leukemia. The company's main operational base is situated in Berkeley Heights, New Jersey.


Net sales
Gross margin
Net income